Assessment of Bone Status in Inhaled Corticosteroid User Asthmatic Patients with an Ultrasound Measurement Method

• Published in: Allergology international Vol. 60; no. 4; pp. 459 - 465
• Main Authors: Sasagawa, Mayumi, Hasegawa, Takashi, Kazama, Jun-ichiro J, Koya, Toshiyuki, Sakagami, Takuro, Suzuki, Kazuo, Hara, Katsuhito, Satoh, Hideo, Fujimori, Katsuya, Yoshimine, Fumitoshi, Satoh, Kazuhiro, Narita, Ichiei, Arakawa, Masaaki, Gejyo, Fumitake, Suzuki, Eiichi
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 2011; Elsevier
• Subjects: Administration, Inhalation; Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - adverse effects; adult asthma; adverse drug reaction; Aged; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - adverse effects; asthma; Asthma - complications; Asthma - drug therapy; Bone and Bones - diagnostic imaging; Bone and Bones - drug effects; bone status; Calcaneus - diagnostic imaging; Calcaneus - drug effects; Female; Humans; inhaled corticosteroid; Male; Middle Aged; Ultrasonography; OSRT; OSI; YAM; asthma; FP; inhaled corticosteroid; BDP; BUD; LTRA; adult asthma; adverse drug reaction; DEXA; TI; bone status; SOS; LABA; BMD; ICS; COPD
• ISSN: 1323-8930; 1440-1592
• DOI: 10.2332/allergolint.10-OA-0276

The effect of inhaled corticosteroid (ICS) on the bone status of asthmatic patients is still uncartain, becuase it can differ by race and because there have been few cases in Japan. In this study, the bone status of ICS users with asthma was evaluated in an actual clinical setting in Japan. In 7 participating hospitals, ICS users with asthma and control subjects were age- and gender-matched and recruited into this study. To assess bone status, ultrasound measurements of each individual's calcaneus were made using an AOS-100. The ratio of the osteo sono-assessment index (OSI) to the average OSI corrected for age and gender was denoted as %OSI and used for quantitative assessment. The second %OSI measurement was performed 6 months after the first %OSI one. During the study period, individual treatment remained unchanged. There were no significant differences in the 1st and 2nd %OSI between the ICS users and control subjects. However, the 2nd %OSI significantly decreased compared with 1st %OSI in female ICS users, although there were no significant changes in the male and female control subjects and male ICS users. The 6 month manegement of asthma in the actual clinical setting, including regular ICS use, might have a harmful influence on the bone status of female asthmatic patients. It may be necessary to manage and treat female patients for potent corticosteroid-induced osteoporosis, although further analyses of bone status in asthma patient ICS users will be required.